Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Disitamab Vedotin Injection — 2.0mg/kg, intravenous infusion,D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
  • Drug: Pertuzumab Injection — Initial dose 840mg, after 2nd dose 420mg intravenous infusion, every 3 weeks
  • Drug: Toripalimab — 3.0 mg/kg, intravenous infusion, D1, every 2 weeks

Primary Outcomes

  • Pathological complete response (pCR) rate (ypT0/is ypN0) (1 month after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-28
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RemeGen Co., Ltd.
Principal Investigators:
  • Jianmin Fang, Ph.D (STUDY_DIRECTOR) - RemeGen Co., Ltd.
Contact Information
Study Contact:
Jianmin Fang, Ph.D
+8610-58075763
Jianminfang@hotmail.com
Jiong Wu, Ph.D
Fudan University Shanghai Cancer Center
Interventions
  • Drug: Disitamab Vedotin Injection — 2.0mg/kg, intravenous infusion,D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
  • Drug: Pertuzumab Injection — Initial dose 840mg, after 2nd dose 420mg intravenous infusion, every 3 weeks
  • Drug: Toripalimab — 3.0 mg/kg, intravenous infusion, D1, every 2 weeks
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200433 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily participate and sign the informed consent form; 2. Ages≥18 years; 3. Histopathologically confirmed invasive breast cancer, clinical stage T2-3 (tumor diameter \> 2 cm), cN0- 3, M0; 4. Invasive breast tumour tissue confirmed HER2-positive by the central laboratory, defined as HER2 protein expression of IHC 3+ by immunohistochemistry (IHC) or IHC 2+ with amplification by in situ hybridisation (ISH) (according to the HER2 Guidelines for Breast Cancer, 2019 edition); and specimens from the primary site of the tumour for HER2 testing (wax blocks, sections or fresh tissue are acceptable) can be provided for HER2 testing; 5. Subjects who tolerate and are scheduled to undergo radical breast cancer surgery and have not received any prior anti-tumour systemic therapy for breast cancer, as assessed by site. 6. At least one measurable lesion according to RECIST v1.1 criteria; 7. Cardiac function: New York Heart Association (NYHA) class \<3; left ventricular ejection fraction ≥55%; 8. Bone marrow or organ function, the following criteria should be met within 7 days prior to study dosing (normal values are based on the clinical trial centre, no transfusion of blood, haematopoietic stimulating factors, albumin or blood products within 14 days prior to the test): haemoglobin ≥ 90 g/L; absolute neutrophil count (ANC) ≥ 1.5 × 109 /L; platelets ≥ 100 × 109 /L; serum total bilirubin ≤ 1.5 times the Upper Limit of Normal (ULN); Albuminous Transaminase (AST) and Albuminous Transaminase (ALT) ≤ 2.5 × ULN; International Normalised Ratio (INR) and Activated Fractional Thromboplastin Time ≤ 1.5 × ULN; and Creatinine Clearance (CrCl) ≥ 50 mL/min according to the Cockcroft-Gault formula method; 9. Subjects of childbearing potential who meet the following criteria: 1. A serum pregnancy test (minimum sensitivity of 25 mIU/mL or equivalent units of β-human chorionic gonadotropin \[β-hCG\]) must be negative within 72 hours prior to the first dose of study intervention. Subjects with false-positive results and confirmed non-pregnancy will be eligible for participation in the study. 2. Must agree to contraception for the duration of the study and for at least 6 months after the last dose of study drug (7 months after the last dose of patulizumab). 3. Must agree not to breastfeed or donate eggs from the time of signing the informed consent until 6 months after the last dose of study drug (7 months after the last dose of patulizumab). 4. If sexually active and likely to result in pregnancy, use of at least 2 acceptable contraceptive methods, at least 1 of which must be highly effective, must be continued from the time of informed consent for at least 6 months after the last dose of study drug (7 months after the last dose of patulizumab). 10. Subjects of childbearing potential who meet the following criteria: 1. Must agree not to donate sperm from the time of signing the informed consent until at least 4 months after the last dose of study drug (7 months after the last dose of patulizumab). 2. If sexual intercourse with a person of childbearing potential is likely to result in pregnancy, the use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective, must be continuous, beginning at the time of informed consent and continuing until at least 4 months after the last dose of study drug (7 months after the last dose of patuximab). 3. If sex with a pregnant or breastfeeding patient, condom use must be continued from the start of informed consent and continue until at least 4 months after the last dose of study drug (7 months after the last dose of patuximab). 12\. Be able to understand the requirements of the trial and be willing and able to comply with the trial and follow up procedural arrangements. Exclusion Criteria: 1. With bilateral invasive breast cancer 2. Previous history of invasive breast cancer 3. Previous carcinoma in situ of the breast with adjuvant endocrine therapy within 5 years of surgery 4. Prior treatment with PD-(L)1, PD-L2, CTLA4 inhibitors and other antibody-coupled drugs 5. Prior anti-HER2 therapy including but not limited to ADC 6. Use of investigational drugs or major surgery within 4 weeks prior to start of study drug administration 7. Vaccination with live or live attenuated vaccine within 4 weeks prior to the start of study drug administration or planned for the duration of the study; 8. History of previous allogeneic haematopoietic stem cell transplantation or organ transplantation; 9. Uncontrolled or significant cardiovascular disease, including (but not limited to): any of the following within 6 months prior to the first dose: e.g., congestive heart failure (NYHA class III or IV), myocardial infarction or cerebral infarction (except for lacunar cerebral infarction), pulmonary embolism, unstable angina, or arrhythmia requiring treatment at screening; primary cardiomyopathy (e.g., dilated cardiomyopathy, Primary cardiomyopathies (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, indeterminate cardiomyopathy); history of clinically significant prolongation of the QTc period, grade II type II AV block or grade III AV block or QTc interval (F method) \>470 msec (women) or \>450 msec (men); atrial fibrillation (EHRA grade ≥2b); uncontrolled hypertension that is judged by the investigator to be unsuitable; and Hypertension, judged by the investigator to be unsuitable for participation in the study; 10. History of interstitial lung disease requiring treatment or current severe lung disease including, but not limited to, active tuberculosis, interstitial lung disease; 11. A clear past or present history of a neurological or psychiatric disorder, including epilepsy or dementia; 12. Persistent grade ≥2 sensory or motor neuropathy; 13. Active infection requiring systemic therapy; active infection requiring systemic therapy ≤7 days prior to study drug administration, with routine antimicrobial prophylaxis permitted; positive HIV test results; patients with active hepatitis B or C (HBsAg positivity with HBV DNA titres above the upper limit of normal; HCVAb positivity with HCV RNA titres above the upper limit of normal); and persistent coronavirus (COVID-19) infection. 14. Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., use of corticosteroids or immunosuppressive drugs, etc.), allowing for related replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency); 15. Other malignancy within 5 years prior to signing the Informed Consent Form (with the exception of non-melanoma skin cancer, cervical carcinoma in situ, limited prostate cancer, stage I endometrial cancer, or other tumours that have been effectively treated and are considered to have been cured); 16. Hypersensitivity reactions or delayed hypersensitivity reactions to certain components of vedicilizumab, patulizumab and treprostinil or similar drugs are known; 17. A concomitant disease that, in the judgement of the investigator, is a serious hazard to the safety of the subject or interferes with the subject's ability to complete the clinical study;
Conditions Genitourinary Syndrome of Menopause (GSM...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to find out whether non-ablative radiofrequency (RF) applied together with pelvic-floor muscle exercises can ease vaginal dryness and other symptoms of genitourinary syndrome of menopause (GSM) in women aged 18-75 years who have survived breast cancer and currently experience those symptoms. The main questions it aims to answer are: Does the combination of RF + exercise lower the 0-to-10 vaginal-dryness score more than sham (inactive) RF + exercise at 6 weeks (end of treatment) and 3 months? What other changes (pain during intercourse, Vaginal Health Index, urinary and sexual function, pelvic-floor strength, overall satisfaction) are seen in each group? Researchers will compare six sessions of active RF with six sessions of sham (inactive) RF to see whether the active treatment works better. Participants will: Visit the hospital once a week for 6 weeks. Each visit includes about 20 minutes of intra-/extra-vaginal RF (or sham) and 20 minutes of guided pelvic-floor training whose content is adapted and progressed throughout the study. Carry out a structured, progressive home-exercise programme, recording any discomfort in a diary. Complete questionnaires and tests at baseline, after session 6, and 3 months later.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active Radiofrequency (Capenergy C500 UpGradeC200) — Non-ablative radiofrequency is applied using a Capenergy C500 device at a target tissue temperature of ≤ 45 °C, once a week for 6 consecutive weeks. Treatment is delivered through two channels simultaneously: a capacitive plate placed on the suprapubic area and an intracavitary vaginal probe. Each session lasts 20 minutes and is followed by 20 minutes of pelvic-floor muscle training guided by biofeedback. Participants will also follow a progressive home exercise programme and record adherence and events. In addition, all participants will receive education on pelvic-floor anatomy and function, underlying mechanisms of pain after breast cancer, bladder and bowel retraining, respiratory pattern re-education, and-if interested-information on sexual health.
  • Device: Sham Radiofrequency (Capenergy C500 UpGrade C200 - Placebo Mode) — Participants will receive one session per week for 6 weeks of sham (placebo) radiofrequency using the Capenergy C500 in Placebo Mode (no temperature increase), designed to simulate active treatment. The screen will display a simulated "delivered energy" value; temperature and energy readings will be hidden; LED indicators will activate sequentially; and a suprapubic capacitive plate and intracavitary probe will be used with the same protocol as in the intervention group. This will be followed by 20 minutes of pelvic-floor muscle training guided by biofeedback, identical to the intervention group. Participants will also follow a progressive home exercise programme and record adherence and events. All participants will receive education on pelvic-floor function, pain mechanisms after breast cancer, bladder/bowel retraining, breathing pattern correction, and-if interested-sexual health.

Primary Outcomes

  • Subjective sensation of vaginal dryness (T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Collaborators: Hospital Universitario Ramon y Cajal
Contact Information
Study Contact:
Irene Lázaro Navas, PhD, MSc, PT
+34 91 336 83 22
ilazaro@salud.madrid.org
Irene Lázaro Navas, PhD, MSc, PT
+34 913368000
irenelazarofisioterapia@gmail.com
Hospital Universitario Ramón y Cajal
Interventions
  • Device: Active Radiofrequency (Capenergy C500 UpGradeC200) — Non-ablative radiofrequency is applied using a Capenergy C500 device at a target tissue temperature of ≤ 45 °C, once a week for 6 consecutive weeks. Treatment is delivered through two channels simultaneously: a capacitive plate placed on the suprapubic area and an intracavitary vaginal probe. Each session lasts 20 minutes and is followed by 20 minutes of pelvic-floor muscle training guided by biofeedback. Participants will also follow a progressive home exercise programme and record adherence and events. In addition, all participants will receive education on pelvic-floor anatomy and function, underlying mechanisms of pain after breast cancer, bladder and bowel retraining, respiratory pattern re-education, and-if interested-information on sexual health.
  • Device: Sham Radiofrequency (Capenergy C500 UpGrade C200 - Placebo Mode) — Participants will receive one session per week for 6 weeks of sham (placebo) radiofrequency using the Capenergy C500 in Placebo Mode (no temperature increase), designed to simulate active treatment. The screen will display a simulated "delivered energy" value; temperature and energy readings will be hidden; LED indicators will activate sequentially; and a suprapubic capacitive plate and intracavitary probe will be used with the same protocol as in the intervention group. This will be followed by 20 minutes of pelvic-floor muscle training guided by biofeedback, identical to the intervention group. Participants will also follow a progressive home exercise programme and record adherence and events. All participants will receive education on pelvic-floor function, pain mechanisms after breast cancer, bladder/bowel retraining, breathing pattern correction, and-if interested-sexual health.
Study Locations (1 sites)
Hospital Universitario Ramón y Cajal, Madrid, Madrid 28034 Spain
Eligibility Criteria
Inclusion Criteria: * Women who are breast cancer survivors and clinically confirmed to be disease-free by their physician. * Amenorrhea for more than 12 months and vaginal pH ≥ 5, with symptoms related to genitourinary syndrome of menopause (GSM), as diagnosed by a physician. Symptoms must be bothersome and not better explained by another clinical condition. * Negative urine culture at baseline. * Moderate to severe vaginal dryness, defined as a score \> 4 on the Numeric Rating Scale (NRS 0-10) Exclusion Criteria: * Age over 75 years. * Current or past diagnosis of any cancer other than breast cancer. * Pelvic surgery, chemotherapy, or radiotherapy in the past 3 months. * Use of local estrogen therapy within the past month. * Active genital infections. * Diagnosis of HIV infection or severe immunosuppression. * Presence of pacemakers, metallic implants, or electromagnetic devices. * Coagulation disorders or current use of anticoagulants. * Pelvic organ prolapse stage \> III (POP-Q classification). * Unexplained abnormal vaginal bleeding. * History of pelvic anti-incontinence surgery, with or without mesh. * Inflammatory dermatoses of the vulva. * Pelvic-floor muscle strength score of 0/5 on the Modified Oxford Scale. * Nickel allergy. * Previous treatment with radiofrequency in the pelvic or genital area.
Conditions Metastatic Breast Cancer, Breast Cancer,...
Phase PHASE1
Enrollment 30
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pembrolizumab — Participants will receive Pembrolizumab as part of standard of care treatment.
  • Device: Cryoablation — Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
  • Device: Histotripsy — Histotripsy of the liver is a noninvasive, nonthermal ablation technique that employs high intensity focused ultrasound pulses to mechanically disrupt targeted hepatic tissues- typically liver tumors-via a process known as acoustic cavitation.

Primary Outcomes

  • Change in CD4-PD1 from baseline to post-ablation (6 weeks after cryoablation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-01-29
Completion: 2027-01-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Yolanda Bryce, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Yolanda Bryce, MD
212-639-6530
brycey@mskcc.org
Larry Norton, MD
646-888-5319
nortonl@MSKCC.ORG
Yolanda Bryce, MD
212-639-6530
Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)
Interventions
  • Drug: Pembrolizumab — Participants will receive Pembrolizumab as part of standard of care treatment.
  • Device: Cryoablation — Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
  • Device: Histotripsy — Histotripsy of the liver is a noninvasive, nonthermal ablation technique that employs high intensity focused ultrasound pulses to mechanically disrupt targeted hepatic tissues- typically liver tumors-via a process known as acoustic cavitation.
Study Locations (7 sites)
Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years of age * Confirmed histologic diagnosis of metastatic TNBC or locally advanced inoperable TNBC * 1 site amenable cryoablation of at least 1.5 cm in size as determined by an Interventional Radiologist. Eligible cryoablation sites include (but not limited to) soft tissue, liver, lung, and bone as determined by an Interventional Radiologist to be safest and most feasible. * Physically fit (clinically eligible) to undergo ablation as per usual clinical practice * Per clinical guidelines, women of childbearing age should use effective contraception during treatment with pembrolizumab and for at least 4 months after the last dose of the drug, which will be assessed and monitored by, and the responsibility of, the patient's medical oncologist (not study investigators or research team) as pembrolizumab is standard of care. Memorial Sloan Kettering Cancer Center Pregnancy Standards will be followed prior to ablation. That is, female patients that are 11-50 years of age and of childbearing potential will undergo a pregnancy test within 2 weeks (15 days) before ablation. Pregnancy test will not be required in patients with bilateral oophorectomy, bilateral salpingectomy, bilateral salpingectomy-oophorectomy, hysterectomy, menopause (no menses ≥ 1 year prior to treatment or after completion of all treatment), or surgical sterilization (i.e. tubal ligation or blockage), with documentation of permanent exemptions in CIS ("Pregnancy Testing Exemption"). * Pembrolizumab therapy (200 mg every 3 weeks) planned as part of standard of care as first, second, or third line of therapy * Eligible for PD-1 inhibitor per the patient's medical oncologist, with planned treatment with PD-1 inhibitor per the patient's medical oncologist. Additional systemic therapy is per the patient's medical oncologist. The following systemic therapy will be accepted (the timing of the systemic therapy relative to pembrolizumab and ablation is not restricted): * Capecitabine (Xeloda, available as a generic drug) * Carboplatin (Paraplatin, available as a generic drug) * Cisplatin (Platinol, available as a generic drug) * Cyclophosphamide (Cytoxan, available as a generic drug) * Docetaxel (Taxotere) * Doxorubicin (Adriamycin, available as a generic drug) * Pegylated liposomal doxorubicin (Doxil) * Epirubicin (Ellence, available as a generic drug) * Eribulin (Halaven) * Fluorouracil (5-FU, Adrucil, available as a generic drug) * Gemcitabine (Gemzar, available as a generic drug) * Ixabepilone (Ixempra) * Methotrexate (available as a general drug) * Nab-paclitaxel (Abraxane) * Paclitaxel (Taxol, available as a generic drug) * Vinorelbine (Navelbine, available as a generic drug) Exclusion Criteria: * Patient not eligible for PD-1 inhibitor per the patient's medical oncologist * No disease amenable for ablation * Pembrolizumab therapy not planned as part of standard of care

HER2-positive Breast Cancer Registry

NCT06603597
Recruiting
Conditions HER2 + Breast Cancer
Phase Not Applicable
Enrollment 1000
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Overall survival rate (From diagnosis to 5 years after diagnosis)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-27
Completion: 2044-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Priyanka Sharma
Contact Information
Study Contact:
Study Coordinator
913-588-6079
PRO-HER2@kumc.edu
Study Coordinator
913-588-6079
PRO-HER2@kumc.edu
The University of Kansas Cancer Center
Interventions
N/A
Study Locations (6 sites)
KUCC - Indian Creek, Overland Park, Kansas 66211 United States
KUCC - Overland Park, Overland Park, Kansas 66215 United States
KUCC - Briarcliff, Westwood, Kansas 66205 United States
KUCC - Olathe, Westwood, Kansas 66205 United States
The University of Kansas Cancer Center, Westwood, Kansas 66205 United States
KUCC - Lee's Summit, Lee's Summit, Missouri 64064 United States
Eligibility Criteria
Inclusion Criteria: * Stage I-IV HER2-positive breast cancer Exclusion Criteria: * None
Conditions Breast Carcinoma, Prostate Cancer Surger...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this. PositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner. The overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: Single intravenous injection of the radiotracer — * only in case of 18F-FDG as PET-tracer: blood glucose level is measured; * single intravenous injection of the radiotracer between 30 minutes and 5 hours (ideally between 60 and 90 minutes) before the specimen is imaged. The type and dose of radiotracer depends on the patient group: * breast cancer group: 0.8 MBq/kg of 18F-FDG * prostate cancer group: 1 MBq/kg 18F-PSMA * thyroid cancer group: 1 MBq/kg of 18F-FDG * parathyroid adenoma group: 1 MBq/kg of 18F-Choline * head \& neck cancer group: 1 MBq/kg of 18F-FDG * skin cancer group: 4 MBq/kg of 18F-FDG * primary and secondary hepatobiliary tumors group: 1 MBq/kg of 18F-FDG * genitourinary malignancies group: 1 MBq/kg of 18F-FDG * metabolic active lesions undergoing biopsy: 1 MBq/kg of 18F-FDG * Neuro-endocrine malignancies group: 1 MBq/kg of 18F-FDG * Brain tumor group: 1 MBq/kg of 18F-FDG, 18F-Choline or 18F * Gastrointestinal group: 1 MBq/kg of 18F-FDG * Thoracovascular group: 1MBq/kg of 18F-FDG
  • Diagnostic Test: Imaging resected specimen using the high-resolution PET-CT specimen imager — * the resected specimen is imaged in the operation theatre using the high-resolution PET-CT specimen imager (XEOS Aura; XEOS Medical, Ghent, Belgium); in principle no treatment decisions will be taken based on the images acquired by the specimen imager; however a decision to extend the resection can be taken at the discretion of the surgeon if there is clinical suspicion of a positive resection margin; * additional resected tissue (e.g. lymph nodes, cavity shaves etc) could also be imaged by the high-resolution PET-CT specimen imager; no treatment decisions will be taken based on the images acquired by the specimen imager;

Primary Outcomes

  • Correlation of margin status (Up to 2 weeks after surgery (histopathology results))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-06
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Algemeen Ziekenhuis Maria Middelares
Contact Information
Study Contact:
Tessa Van Oostveldt
+3292468000
klinische.studies@mijnziekenhuis.be
Steffi Ryckaert
003292461851
steffi.ryckaert@mijnziekenhuis.be
Steffi Ryckaert, Clinical Research Centre Manag
+32 9 246 18 51
steffi.ryckaert@mijnziekenhuis.be
AZ Maria Middelares
Interventions
  • Other: Single intravenous injection of the radiotracer — * only in case of 18F-FDG as PET-tracer: blood glucose level is measured; * single intravenous injection of the radiotracer between 30 minutes and 5 hours (ideally between 60 and 90 minutes) before the specimen is imaged. The type and dose of radiotracer depends on the patient group: * breast cancer group: 0.8 MBq/kg of 18F-FDG * prostate cancer group: 1 MBq/kg 18F-PSMA * thyroid cancer group: 1 MBq/kg of 18F-FDG * parathyroid adenoma group: 1 MBq/kg of 18F-Choline * head \& neck cancer group: 1 MBq/kg of 18F-FDG * skin cancer group: 4 MBq/kg of 18F-FDG * primary and secondary hepatobiliary tumors group: 1 MBq/kg of 18F-FDG * genitourinary malignancies group: 1 MBq/kg of 18F-FDG * metabolic active lesions undergoing biopsy: 1 MBq/kg of 18F-FDG * Neuro-endocrine malignancies group: 1 MBq/kg of 18F-FDG * Brain tumor group: 1 MBq/kg of 18F-FDG, 18F-Choline or 18F * Gastrointestinal group: 1 MBq/kg of 18F-FDG * Thoracovascular group: 1MBq/kg of 18F-FDG
  • Diagnostic Test: Imaging resected specimen using the high-resolution PET-CT specimen imager — * the resected specimen is imaged in the operation theatre using the high-resolution PET-CT specimen imager (XEOS Aura; XEOS Medical, Ghent, Belgium); in principle no treatment decisions will be taken based on the images acquired by the specimen imager; however a decision to extend the resection can be taken at the discretion of the surgeon if there is clinical suspicion of a positive resection margin; * additional resected tissue (e.g. lymph nodes, cavity shaves etc) could also be imaged by the high-resolution PET-CT specimen imager; no treatment decisions will be taken based on the images acquired by the specimen imager;
Study Locations (1 sites)
AZ Maria Middelares, Ghent, Oost Vlaanderen 9000 Belgium
Eligibility Criteria
A. Inclusion Criteria: * able to understand treatment protocol and informed consent form * estimated by the investigator to be compliant for study participation 1\. Fulfilling all group-specific inclusion criteria: * confirmed breast cancer with an indication to undergo breast conserving surgery * confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy; * confirmed thyroid lesion with an indication to undergo resective surgery; * confirmed parathyroid adenoma with an indication to undergo resective surgery; * suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery; * suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery; * suspected lesion in the head \& neck region with an indication to undergo resective surgery; * confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery; * patients undergoing biopsy after metabolic active lesions were detected on a PET scan. * suspected neuro-endocrine malignancies with an indication to undergo resective surgery. * suspected brain tumor with an indication to undergo resective surgery. * Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery. * suspected malignant thoracovascular lesions with an indication to undergo resective surgery B. Exclusion Criteria: * general or local contra-indications for resective surgery; * in case of FDG-based PET tracers: a blood glucose level over 200 mg/dL on the day of surgery; * pregnancy or lactation; * participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Purpose: This study will evaluate how measurements of tissue stiffness, viscosity, and anisotropy using non-invasive ultrasound imaging correlate with breast tumor malignancy and response to chemotherapy. Participants: Up to 200 women with benign or malignant breast tumors for arm 1 and up to 50 women undergoing neoadjuvant chemotherapy in the breast for arm 2 will be recruited. Procedures (methods): The research team will use an ultrasound scanner to acquire non-invasive elastography data from the breast of each subject, testing a range of transducer rotation angles. Transducer position will be monitored using a position sensor during imaging.

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Device: Ultrasound — Non-invasive breast imaging using VisR ultrasound

Primary Outcomes

  • ARFI Peak Displacement (PD) in lesion (Study Arm 1) (Baseline imaging)
  • ARFI Peak Displacement (PD) in surrounding tissue (Study Arm 1) (Baseline imaging)
  • VisR Relative Elasticity (RE) in lesion (Study Arm 1) (Baseline imaging)
  • VisR Relative Elasticity (RE) in surrounding tissue (Study Arm 1) (Baseline imaging)
  • VisR Relative Viscosity (RV) in lesion (Study Arm 1) (Baseline imaging)
  • VisR Relative Viscosity (RV) in surrounding tissue (Study Arm 1) (Baseline imaging)
  • ARFI PD DoA in lesion (Study Arm 1) (Baseline imaging)
  • ARFI PD DoA in surrounding tissue (Study Arm 1) (Baseline imaging)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-07
Completion: 2028-02-24
Eligibility
Age: 20 Years – 90 Years
Sex: FEMALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Caterina Gallippi, PhD (PRINCIPAL_INVESTIGATOR) - Lampe Joint Department of Biomedical Engineering
Contact Information
Study Contact:
Desma Jones
919-843-9463
desma_jones@med.unc.edu
Caterina Gallippi, PhD
9198436647
cmgallip@email.unc.edu
Desma Jones
984-974-8771
desma_jones@med.unc.edu
University of North Carolina at Chapel Hill
Interventions
  • Device: Ultrasound — Non-invasive breast imaging using VisR ultrasound
Study Locations (1 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514 United States
Eligibility Criteria
Inclusion Criteria (Arm 1): * Subjects are 20-90 years of age * Subjects are female * Breast lesion is sonographically visible with B-Mode ultrasound on diagnostic workup * Breast lesion(s) have BI-RADS 4a, 4b, 4c, or 5 rating Exclusion Criteria (Arm 1): * Inability to provide informed consent * Inability to communicate in English * Inability to remain motionless for 15 minutes * Subjects with breast implants * Breast mass is deeper than 4 cm from skin surface * Subjects who are pregnant or lactating * Subjects who have pacemakers or implanted cardioverters * Subjects with a history of mastectomy * Previous biopsy or surgery to the site of the mass, surgical excision of mass of interest * Subject is male Inclusion Criteria (Arm 2): * Subjects are 20-90 years of age * Subjects are female * Breast lesion is sonographically visible with B-Mode ultrasound on diagnostic workup * Breast lesion(s) have BI-RADS 6 rating, subject will be undergoing NAT for stage 2 or 3 malignant breast lesion(s) Exclusion Criteria (Arm 2): * Inability to provide informed consent * Inability to communicate in English * Inability to remain motionless for 15 minutes * Subjects with breast implants * Breast mass is deeper than 4 cm from skin surface * Subjects who are pregnant or lactating * Subjects who have pacemakers or implanted cardioverters * Subjects with a history of mastectomy * Previous biopsy or surgery to the site of the mass, surgical excision of mass of interest * Subject is male
Conditions Breast Cancer
Phase NA
Enrollment 150000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Double

Interventions / Regimen

  • Other: AI assisted mammography screening interpretation — Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of \>9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
  • Other: Standard mammography screening interpretation — Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.

Primary Outcomes

  • Screen-detected breast cancers (36 months from study start-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-25
Completion: 2033-06
Eligibility
Age: 50 Years – 69 Years
Sex: FEMALE
Volunteers: true
Enrollment: 150000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Norwegian Institute of Public Health
Collaborators: Helse Vest, Helse Midt-Norge, Helse Nord, Norwegian Cancer Society
Principal Investigators:
  • Solveig Hofvind, PhD (PRINCIPAL_INVESTIGATOR) - Norwegian Institute of Public Health
Contact Information
Study Contact:
Solveig Hofvind, PhD
22928828
sshh@kreftregisteret.no
Åsne S Holen, MSc
asho@kreftregisteret.no
Solveig Hofvind, PhD
+4722928828
sshh@kreftregisteret.no
Cancer Registry of Norway, Norwegian Institute of Public Health
Interventions
  • Other: AI assisted mammography screening interpretation — Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of \>9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
  • Other: Standard mammography screening interpretation — Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
Study Locations (1 sites)
Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway
Eligibility Criteria
Inclusion Criteria: * Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent Exclusion Criteria: * Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent
Conditions Breast Cancer, HER2-positive Breast Canc...
Phase PHASE2
Enrollment 71
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalcilib+letrozole+HP treatment group — All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days. Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.

Primary Outcomes

  • pathologic complete response (Immediately after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-01-20
Completion: 2029-06-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 71 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Principal Investigators:
  • Zhenzhen Liu (PRINCIPAL_INVESTIGATOR) - Henan Cancer Hospital
Contact Information
Study Contact:
Zhenzhen Liu
0371-65587005
liuzhenzhen73@126.com
Dechuang Jiao
0371-65588380
jiaodechuang@163.com
Zhen Liu
13838308034
Henan cacer hospital
Interventions
  • Drug: Dalcilib+letrozole+HP treatment group — All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days. Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Study Locations (1 sites)
Henan cacer hospital, Henan, Henan 450008 China
Eligibility Criteria
Inclusion Criteria: 1. Female initial treatment patients aged ≥ 18 years and ≤ 70 years. 2. ECOG score 0-1 points. 3. Pathologically confirmed as invasive breast cancer, with tumor staging of II-IIIA. 4. HR positive HER-2 positive. 5. The main organs function normally and meet the following standards: (1)The blood routine examination standards must comply with:ANC ≥1.5×10 9/L;PLT ≥100×109/L;Hb ≥90g/L. (2)Biochemical examination must meet the following standards: TBIL ≤ 1.5 Upper limit of normal value (ULN);ALT and AST ≤ 1.5 times the upper limit of normal value (ULN);Alkaline phosphatase ≤ 2.5 times the upper limit of normal value (ULN);BUN and Cr ≤ 1.5 × ULN and creatinine clearance rate ≥ 50 mL/min; (3)Cardiac ultrasound and echocardiography: Left ventricular ejection fraction (LVEF ≥ 50%). 6\. For female patients who have not undergone menopause or surgical sterilization: Agree to abstain or use effective contraceptive methods during the treatment period and at least 7 months after the last administration during the study treatment. 7\. Volunteer to join this study and sign an informed consent form. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer. 2. inflammatory breast cancer. 3. Previously received anti-tumor therapy or radiation therapy for any malignant tumor, excluding cured cervical cancer in situ, basal cell carcinoma, or squamous cell carcinoma. 4. Simultaneously receiving anti-tumor therapies in other clinical trials, including endocrine therapy, bisphosphate therapy, or immunotherapy. 5. The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures. 6. Individuals who have previously suffered from clinically significant lung diseases, including but not limited to interstitial pneumonia, pneumonia, pulmonary fibrosis, and radiation pneumonia (excluding radiation changes that do not require corrective treatment), or those who have been found to have such diseases through screening period examinations. 7. Serious heart disease or discomfort, including but not limited to the following diseases: (1)Confirmed history of heart failure or systolic dysfunction (LVEF\<50%). (2)High risk uncontrolled arrhythmia(atrial tachycardia,ventricular tachycardia,Higher level atrioventricular block); (3)Angina pectoris requiring treatment with anti angina drugs; (4)Clinically significant heart valve disease; (5)ECG shows transmural myocardial infarction; (6)Poor control of hypertension (systolic blood pressure\>180 mmHg and/or diastolic blood pressure\>100 mmHg); 8. Inability to swallow, intestinal obstruction, or other factors that affect drug administration and absorption. 9\. Individuals with a known history of allergies to the drug components of this protocol;Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation. 10\. Pregnant and lactating female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study medication. 11\. Suffering from severe comorbidities or other comorbidities that may interfere with the planned treatment, or any other situation where the researcher deems the patient unsuitable to participate in this study.
Conditions Breast Cancer
Phase NA
Enrollment 311
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized, monocentric, non-inferiority interventional clinical study comparing an Accelerated Partial Breast Irradiation (APBI) for the surgical bed of early-stage breast cancer patients with favorable histological subtypes, using stereotactic radiotherapy in a single dose of 15.5 Gy with Simultaneous Integrated Boost (SIB) to 21 Gy (study treatment, delivered in a single fraction) versus multifractionated radiotherapy of 30 Gy in 5 fractions (standard treatment, delivered in 5 fractions).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Adjuvant single-fraction accelerated partial breast irradiation — Experimental arm (arm 1-single-fraction APBI) patients will be treated to a total dose (TD) of 15.5 Gy to the PTV with a simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed, while arm 2-five-fractions APBI patients with 30 Gy/ 5 fractions to PTV.

Primary Outcomes

  • Ipsilateral Breast Tumor Recurrence (IBTR) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-25
Completion: 2035-06-30
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 311 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS San Raffaele
Principal Investigators:
  • Andrei Fodor, MD (PRINCIPAL_INVESTIGATOR) - IRCCS San Raffaele Scientific Institute
Contact Information
Study Contact:
Andrei Fodor, MD
+390226437634
fodor.andrei@hsr.it
Nadia G Di Muzio, Prof
+390226437643
dimuzio.nadia@hsr.it
Andrei Fodor, MD
+390226437634
fodor.andrei@hsr.it
IRCCS San Raffaele Scientific Institute
Interventions
  • Radiation: Adjuvant single-fraction accelerated partial breast irradiation — Experimental arm (arm 1-single-fraction APBI) patients will be treated to a total dose (TD) of 15.5 Gy to the PTV with a simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed, while arm 2-five-fractions APBI patients with 30 Gy/ 5 fractions to PTV.
Study Locations (1 sites)
IRCCS San Raffaele Scientific Institute, Milan, 20132 Italy
Eligibility Criteria
Inclusion Criteria: 1. Histological diagnosis of breast cancer 2. Patients aged ≥40 years 3. Signed informed consent 4. Stage pTis-T2, up to 3 cm in the greatest diameter 5. Luminal A and Luminal B HER2-negative histological subtypes 6. Negative surgical margins (≥ 0.2 cm) 7. Negative lymph nodes at sentinel lymph node biopsy, or alternatively with imaging tests (Positron Emission Tomography (PET)/Computed Tomography (CT) and/or axillary ultrasound, and/or breast Magnetic Resonance Imaging (MRI) with and without contrast), or, in rare cases, where still performed, with axillary dissection 8. Clinical M0 (PET/CT and/or bone scintigraphy and/or abdomen-pelvis CT with and without contrast in suspected patients), within the previous 3 months. 9. Performance Status (PS) Eastern Cooperative Oncology Group (ECOG) ≤2 10. No prior thoracic radiotherapy 11. Fertile women using contraception methods initiated during oncological treatment. Exclusion Criteria: 1. Patients aged \< 40 years 2. Tumors \> 3 cm 3. Multicentric tumors 4. Positive or close surgical margins (\<0.2 cm) 5. Lobular carcinoma 6. Negative hormone receptors 7. HER2-positive 8. BReast CAncer (BRCA) genes BRCA1 and/or BRCA2 positive (only if known) 9. Severe systemic diseases 10. Psychiatric or other disorders that may prevent the patient from signing informed consent 11. Previous invasive cancer, except for skin cancer (excluding melanoma) unless the patient has been disease-free for at least 3 years (e.g., carcinoma in situ of the oral cavity or bladder) 12. Collagen or autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome) 13. Lymph node disease (N1) 14. Evidence of distant metastasis (M1) 15. Contraindication to systemic treatment 16. Pregnant women 17. Non-compliance with the dose limits established in the treatment plan
Conditions Soft-tissue Sarcoma, Triple Negative Bre...
Phase PHASE1, PHASE2
Enrollment 67
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Spedox-6 — Given Intravenously (IV)
  • Drug: Pegfilgrastim — Given Subcutaneous Injection or IV
  • Drug: Filgrastim — Given Subcutaneous Injection or IV

Primary Outcomes

  • Overall Response Rate (ORR) by RECIST v1.1 (2 Years)
  • Disease Control Rate (DCR) by RECIST v1.1 (2 Years)
  • Complete Response Rate by RECIST v1.1 (2 years)
  • Partial Response Rate by RECIST v1.1 (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-04-30
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 67 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Irvine
Collaborators: Sunstate Biosciences LLC
Principal Investigators:
  • Warren Chow, MD (PRINCIPAL_INVESTIGATOR) - Chao Family Comprehensive Cancer Center
Contact Information
Study Contact:
Chao Family Comprehensive Cancer Center University of California, Irvine
1-877-827-8839
ucstudy@uci.edu
University of California Irvine Medical Center
Warren Chow, MD
877-827-8839
ucstudy@uci.edu
Chao Family Comprehensive Cancer Center University of California, Irvine
Interventions
  • Drug: Spedox-6 — Given Intravenously (IV)
  • Drug: Pegfilgrastim — Given Subcutaneous Injection or IV
  • Drug: Filgrastim — Given Subcutaneous Injection or IV
Study Locations (1 sites)
Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California 92868 United States
Eligibility Criteria
Inclusion Criteria: * Subjects ≥ 18 years at the first screening examination/visit. * Subjects with advanced histologically or cytologically confirmed solid tumors (see below) refractory to or relapse from at least two previous therapies. * Tumor types expected to express lower levels of FcRn relative to normal tissue including: STS, TNBC, cervical cancer, NSCLC, ovarian cancer, and KRAS mutated pancreatic ductal adenocarcinoma without requirement for testing FcRn level. * Disease that is considered measurable by RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Life expectancy of at least 12 weeks. * Human Immunodeficiency Virus (HIV)-positive trial participants should be on established antiretroviral therapy (ART) for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment. * Left ventricular ejection fraction \> 50%. * Adequate organ function: (Hb ≥10 g/dL, ANC ≥1,000/µL3, and platelets ≥100,000/µL3), serum bilirubin ≤.5x the institutional upper limit of normal (ULN) (unless known Gilbert's disease), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤3x ULN, and creatinine clearance \>50 mL/min as assessed by Cockcroft-Gault equation. * For patients with known Gilbert's disease, serum unconjugated bilirubin must be \< 4 mg/dL. * Patient must have washed out of prior chemotherapy (at least 3 weeks from last end of therapy), radiotherapy (at least 4 weeks from last end of therapy), immunotherapy (at least 4 weeks from last end of therapy), other targeted therapies (at least 4 weeks from last end of therapy), or surgery (at least 4 weeks). * Recovery from toxicities of prior therapy. Toxicities should have recovered to CTCAE grade ≤ 1 or baseline with exception of alopecia. * Females of reproductive potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment. Additionally, female subjects of reproductive potential should agree to use effective acceptable forms of contraception: surgical sterilization (tubal ligation); total abstinence from sexual intercourse with the opposite sex; established hormonal birth control (e.g., oral, transdermal, injection, or implant) plus a barrier method or a double barrier method (intrauterine device, spermicide, or a diaphragm plus condom) for at least 1 month prior to Cycle 1 Day 1 and agreement to use such a method during study participation and for an additional 6 months after the last dose of SPEDOX-6. * For males of reproductive potential: vasectomy or highly effective contraception (e.g., condoms, abstinence) during the study and for an additional 6 months after the last dose of SPEDOX-6. Exclusion Criteria: * Patients with cancers with known driver mutations for which there are known and effective targeted therapies that have not received those therapies, but are able to. If a patient has received appropriate targeted treatment for their mutations and progressed, or those treatments are contraindicated, they will be considered potentially eligible. * Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months before study entry. * Untreated metastases to the Central Nervous System (CNS). * Have received any prior doxorubicin or anthracycline equivalent. * Previous radiation to the mediastinal or pericardial area. * A known allergy to albumin. * HIV infection with CD4+ count \< 350 cells/µL or Acquired Immunodeficiency (AIDS)-defining opportunistic infection in previous 12 months. * Pregnant (positive serum or urine pregnancy test) or lactating. * Previous treatment with an investigational agent or the non-approved use of a drug or device withing 4 weeks of study entry. * Uncontrolled diabetes mellitus. * Patients who require concomitant use of strong inhibitors or inducers of CYP3A4, CYP2D6 or P-glycoprotein (P-gp).
Conditions Breast Neoplasms, Breast Cancer
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Neoadjuvant chemotherapy for advanced breast cancer has led to an increased rate of breast-conserving surgery (BCS) in these patients. As the demand for preoperative localization methods grows among surgeons performing BCS, traditional localization techniques have shown limitations. For non-palpable breast lesions, preoperative localization has commonly been achieved using ultrasound-guided skin markings or needle localization. However, these methods present challenges, including difficulty in depth localization for patients with large breasts and limitations in real-time re-verification during surgery due to air artifacts after incision. Needle localization, although commonly used, is invasive and poses risks such as displacement or detachment of the needle. Indocyanine green (ICG), a fluorescent dye that appears green to the naked eye and is detectable by near-infrared (NIR) cameras, has been widely and safely used in clinical practice via intravenous or subcutaneous administration. Recently, ICG combined with NIR imaging has been adopted for sentinel lymph node biopsy in breast cancer and melanoma surgeries and is increasingly used as a localization method for various tumors, replacing conventional techniques. A preliminary study (IRB No. NCC2016-0071) conducted at the institution evaluated ICG injection and NIR fluorescence imaging for tumor localization in early breast cancer patients undergoing BCS. The study demonstrated the efficacy of ICG-based localization in reducing the rate of positive surgical margins. The objective of this study is to evaluate the effectiveness of ICG-guided tumor localization with NIR fluorescence imaging in patients with advanced breast cancer treated with neoadjuvant chemotherapy. It is hypothesized that this technique will allow for more accurate tumor excision compared to conventional methods, ultimately improving surgical outcomes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: The margin-positive rate using the localization technique — Localization of breast cancer using indocyanine green fluorescence (ICG-F)

Primary Outcomes

  • Margin-positive rate in final pathological report (10~35 days after surgery (the date when the pathological reports are available))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-06
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Center, Korea
Principal Investigators:
  • Seeyoun Lee, MD (PRINCIPAL_INVESTIGATOR) - National Cancer Center, Korea
Contact Information
Study Contact:
Seeyoun Lee, MD
+82-31-920-1736
seeyoun@ncc.re.kr
Seeyoun Lee
+82-31-920-1736
seeyoun@ncc.re.kr
National Cancer Center
Kwideuk Son
+82-31-920-0848
75095@ncc.re.kr
National Cancer Center
Interventions
  • Procedure: The margin-positive rate using the localization technique — Localization of breast cancer using indocyanine green fluorescence (ICG-F)
Study Locations (1 sites)
National Cancer Center, Goyang-si, Gyeonggi-do 410-769 South Korea
Eligibility Criteria
Inclusion Criteria: * The Patient with locally advanced breast cancer who is eligible for breast-conserving surgery after receiving neoadjuvant chemotherapy * Aged over 18 years old * ECOG performance status: 0 or 1 * The patients with written informed consent Exclusion Criteria: * The patient who requires total mastectomy after receiving neoadjuvant chemotherapy * The patient with no residual mass on ultrasonography or only with microcalcifications * Pregnant or lactating patient * The patient with a disability to understand and provide consent * The patient with severe allergic history to indocyanine green * Iodine-sensitive patient
Conditions Obesity
Phase NA
Enrollment 45
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This interventional study is part of a broader research project entitled "Bone Marrow Adipose Tissue in Relation to Bone and Energy Metabolism in Obesity and Type 2 Diabetes Mellitus." The broader project includes both a cross-sectional study evaluating bone marrow adipose tissue and bone marrow mesenchymal stem cells in people with different metabolic and bone disorders and the present dietary intervention study. The interventional study investigates whether caloric restriction changes bone marrow adipose tissue, bone health, whole-body metabolism, and the molecular and cellular characteristics of bone marrow mesenchymal stem cells in obese non-diabetic premenopausal women. A group of lean healthy premenopausal women will serve as a comparison group. Participants in the intervention group will undergo an eight-week formula-based very-low-calorie diet using Cambridge Weight Plan products, providing approximately 2.5-3.35 MJ (600-800 kcal) per day, followed by a dietary weight-maintenance phase. Participants will receive nutritional counselling, and dietary adherence, body weight, physical activity, and clinical status will be monitored during scheduled study visits. Clinical and laboratory assessments will be conducted at baseline and after 2, 6, and 12 months. Assessments will include magnetic resonance imaging and proton magnetic resonance spectroscopy of the lumbar spine to measure the amount and lipid composition of vertebral bone marrow adipose tissue. Bone mineral density and body composition will be measured using dual-energy X-ray absorptiometry, with particular attention to bone mineral density at the total hip and femoral neck. Additional measurements will include body weight, waist and hip circumference, body composition, physical activity, and fasting blood tests evaluating bone turnover, glucose and lipid metabolism, inflammatory markers, hormones, and adipokines. Bone marrow aspirates and abdominal subcutaneous adipose tissue biopsies will be obtained at baseline and after six months. Bone marrow-derived and adipose tissue-derived mesenchymal stem cells will be examined for changes in cellular composition, gene-expression profiles, metabolic activity, oxidative stress, differentiation capacity, and senescence-related characteristics. Single-cell RNA sequencing will be used to characterize specific bone marrow mesenchymal stem cell subpopulations. Bone marrow plasma and other biological samples will also undergo metabolomic, lipidomic, and proteomic profiling using high-resolution mass spectrometry. These analyses will be used to identify extracellular molecules and molecular patterns associated with glucose and lipid metabolism, inflammation, cellular senescence, and the response to caloric restriction. The study aims to determine whether diet-induced weight loss can improve the bone marrow microenvironment and modify vertebral bone marrow fat, bone parameters, and the metabolic and senescent phenotype of mesenchymal stem…

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Caloric Restriction — Participants will follow a formula-based very-low-calorie diet (Cambridge Weight Plan) providing approximately 600-800 kcal per day (2.5-3.35 MJ per day) for 8 weeks. This will be followed by a 4-month low-calorie diet phase and subsequently by a weight-maintenance phase. Participants will receive nutritional counselling, and dietary adherence, body weight, physical activity, and clinical status will be monitored during scheduled study visits.

Primary Outcomes

  • Change From Baseline in Mean L2-L4 Vertebral Bone Marrow Adipose Tissue Proton Density Fat Fraction (Baseline, Week 24, and Week 48)
  • Change From Baseline in Mean L2-L4 Vertebral Bone Marrow Adipose Tissue Unsaturation Index (Baseline, Week 24, and Week 48)
  • Change from baseline in BM-MSC and AT-MSC potency, differentiation, senescence, and metabolic adaptation (Baseline and Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-01
Completion: 2027-01-21
Eligibility
Age: 21 Years – 55 Years
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: General University Hospital, Prague
Collaborators: Czech Academy of Sciences, Ministry of Health, Czech Republic
Principal Investigators:
  • Michaela Tencerova, MSc, PhD (PRINCIPAL_INVESTIGATOR) - Institute of Physiology of the Czech Academy of Sciences
Contact Information
Study Contact:
Vit Zikan, MD, Ph.D.
+420731670425
vit.zikan@vfn.cz
Michaela Tencerova, M.Sc., Ph.D.
+420 241 062737
michaela.tencerova@fgu.cas.cz
Ivan Raska, MD, Ph.D.
+420224969280
ivan.raska@vfn.cz
General University Hospital in Prague
Interventions
  • Behavioral: Caloric Restriction — Participants will follow a formula-based very-low-calorie diet (Cambridge Weight Plan) providing approximately 600-800 kcal per day (2.5-3.35 MJ per day) for 8 weeks. This will be followed by a 4-month low-calorie diet phase and subsequently by a weight-maintenance phase. Participants will receive nutritional counselling, and dietary adherence, body weight, physical activity, and clinical status will be monitored during scheduled study visits.
Study Locations (3 sites)
General University Hospital in Prague, Prague, 12800 Czechia
Institute of Endocrinology, Prague, a state-funded organization established by the Ministry of Health of the Czech Republic., Prague, 12800 Czechia
Institute of Physiology of the Czech Academy of Sciences, Prague, 14200 Czechia
Eligibility Criteria
Interventional Study: Effect of Caloric Restriction on BMAT/BM-MSCs Phenotype Inclusion Criteria: * Premenopausal women and age-eligible men assigned to either the obese intervention group or the lean control group * Obese intervention group: * Body mass index (BMI) of 30-42 kg/m² * Fasting plasma glucose less than 6.4 mmol/L * Age 25-55 years * Lean control group: * BMI of 19-25 kg/m² * Fasting plasma glucose less than 6.4 mmol/L * Age 25-50 years Exclusion Criteria: * Diabetes mellitus * Secondary osteoporosis * History of severe neuropathic disease * Hyperparathyroidism * Hyperthyroidism * Immobilization * Alcoholism * Chronic gastrointestinal disease * Significant chronic renal impairment, including any of the following: * Chronic kidney disease * Serum creatinine greater than 110 µmol/L * Estimated glomerular filtration rate (eGFR) less than 1 mL/s/1.73 m² * Proteinuria * Diabetic nephropathy * Chronic hepatic impairment * Unstable cardiovascular disease * Uncontrolled hypertension * Current or recent use of any of the following medications: * Bisphosphonates * Estrogen * Denosumab * Gonadotropin-releasing hormone (GnRH) analogs * Glucocorticoids at a dose equivalent to at least 5 mg of prednisone daily for at least 1 month * Phenytoin * Thiazolidinediones * Insulin * Adrenal or anabolic steroids * Anticonvulsants * Anticoagulants * Pharmacological doses of vitamin D or vitamin A supplements * Contraindications to magnetic resonance imaging (MRI), including: * Pacemaker * Metallic implants incompatible with MRI * Claustrophobia